Kalvista Pharmaceuticals, INC 8-K filings
NASDAQ
8-K: KalVista Pharmaceuticals Terminates $100 Million Equity Offering Agreement with Cantor Fitzgerald
KalVista Pharmaceuticals has terminated its $100 million controlled equity offering sales agreement with Cantor Fitzgerald, effective February 14, 2024.
NASDAQ
8-K: KalVista's Sebetralstat Meets All Endpoints in Phase 3 Trial, Paving Way for Oral HAE Treatment
KalVista Pharmaceuticals announced positive Phase 3 trial results for sebetralstat, demonstrating its potential as the first oral on-demand treatment for hereditary angioedema (HAE).